Compare GTE & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | GLSI |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 244.7M |
| IPO Year | 2007 | 2020 |
| Metric | GTE | GLSI |
|---|---|---|
| Price | $9.86 | $16.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.5M | 111.5K |
| Earning Date | 05-01-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 41.99 | N/A |
| 52 Week Low | $3.09 | $7.78 |
| 52 Week High | $11.52 | $34.10 |
| Indicator | GTE | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 66.09 | 51.01 |
| Support Level | $7.02 | $16.52 |
| Resistance Level | $11.52 | $29.89 |
| Average True Range (ATR) | 0.70 | 1.21 |
| MACD | 0.07 | 0.37 |
| Stochastic Oscillator | 43.84 | 59.56 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. The majority of its revenue comes from operations in Colombia.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.